Saturday 17 October 2026
Export ARDX’s income statement to Excel — free account
Ardelyx, Inc.
ARDX Healthcare Biotechnology
Ardelyx, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $407.3 million, up 22.1% from fiscal 2024. In the quarter to June 2026, revenue grew 23.8%, EPS grew 12.5%, free cash flow grew 75.3% and total debt rose 25.0%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
3.09
0.18
−5.50%
Follow ARDX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
2.81 | 3.44 | 3.45 | 3.35 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(197.71) | (45.68) | 67.07 | 3,651.82 | |
P/B ratio |
8.49 | 9.91 | 8.42 | 8.64 | |
Price to Tangible BV |
8.49 | 9.91 | 8.42 | 8.64 | |
EV/Sales |
2.80 | 3.43 | 3.36 | 3.31 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(72.87) | (40.40) | (32.26) | (24.60) | |
EV/FCF |
(70.44) | (39.07) | (31.16) | (23.84) | |
Quick Ratio |
2.89 | 2.93 | 3.80 | 3.83 | |
Current Ratio |
3.34 | 3.49 | 4.31 | 4.41 | |
Net Debt/EBITDA |
2.54 | 1.08 | (10.27) | (7.28) | |
Debt/Assets |
43.73% | 40.34% | 40.44% | 41.58% | |
Debt/Equity |
1.69 | 1.37 | 1.21 | 1.31 | |
Asset Turnover |
0.86 | 0.94 | 0.87 | 0.93 | |
Operating CF/Net income |
0.38 | 0.86 | (51.48) | (0.38) | |
Capex/Depreciation |
(0.02) | (0.08) | (0.39) | (0.17) | |
Interest Coverage |
(2.00) | (4.74) | 0.67 | 0.58 | |
Research and Development Expense of Revenue |
21.59% | 21.37% | 18.25% | 16.38% | |
Selling, General and Administrative Expense of Revenue |
83.92% | 108.25% | 69.01% | 75.78% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
12.67% | 14.99% | 9.94% | 11.55% | |
Graham Net Nets |
0.01 | 0.02 | 0.03 | 0.03 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(4.39%) | (3.91%) | (4.36%) | (4.25%) | |
Free Cash Flow Yield |
(1.42%) | (2.55%) | (3.13%) | (4.15%) | |
Revenue per Share |
0.49 | 0.38 | 0.52 | 0.46 | |
Operating CF per Share |
(0.03) | (0.13) | 0.09 | 0.00 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.03) | (0.13) | 0.09 | 0.00 | |
Cash per Share |
1.14 | 0.97 | 1.10 | 1.00 | |
Shareholders Equity per Share |
0.60 | 0.60 | 0.69 | 0.64 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.60 | 0.60 | 0.69 | 0.64 | |
Free Cash Flow |
(6.41) | (32.31) | 20.59 | 0.21 | |
Working Capital |
309.71 | 272.30 | 293.71 | 284.60 | |
Capital Expenditures |
(0.01) | (0.07) | (0.36) | (0.16) | |
Net Current Asset Value |
15.05 | 25.99 | 47.66 | 36.10 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
81.45 | 64.65 | 64.78 | 64.90 | |
Average Payables |
30.05 | 20.96 | 17.62 | 17.11 | |
Average Inventory |
24.07 | 23.26 | 19.45 | 18.28 | |
Average Assets |
521.33 | 457.35 | 468.68 | 427.02 | |
Average Common Equity |
144.27 | 147.15 | 170.12 | 156.29 |
Columns are period end dates